Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort
J. Zweegers, B. Roosenboom, P.C.M. van de Kerkhof, J.M.P.A. van den Reek, M.E. Otero, S. Atalay, A.L.A. Kuijpers, M.I.A. Koetsier, W.P. Arnold, M.A. Berends, L. Weppner-Parren, M. Bijen, M.D. Njoo, J.M. Mommers, P.P.M. van Lümig, R.J.B. Driessen, W. Kievit and E.M.G.J. de Jong
Version of Record online: 7 OCT 2016 | DOI: 10.1111/bjd.14888
What's already known about this topic?
- A high clinical response in patients with psoriasis is shifting towards a 90% improvement compared with baseline Psoriasis Area and Severity Index (PASI 90).
- To date, no studies have assessed which patients with psoriasis are more likely to achieve a high clinical response at week 24 of biological treatment.
What does this study add?
- We focused on high responders, defined as achieving PASI 100, PASI 90 or PASI ≤ 5.
- Frequency of reaching high clinical responses at 24 weeks of biological treatment was assessed, as were predictors that could identify patients with the ability to respond well to biological treatment.
- In only a limited number of treatment episodes are PASI 90 (15%) or PASI 100 (3%) achieved.
- Lower baseline body mass index is a predictor for achieving PASI ≤ 5.